The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials.
Marie SelvyMélissa CuménalNicolas KerckhoveChristine CourteixJérôme BusserollesDavid BalayssacPublished in: Expert opinion on drug safety (2020)
Among antiepileptics and antidepressants, duloxetine appeared to have the most detailed safety for the treatment of peripheral neuropathic pain. Over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation. Only 20.0% of the included studies (N = 90) presented a good description of adverse effects that included a statistical comparison vers usa placebo group. Important methodological improvements must be made to improve the assessment of medication safety in future clinical trials.
Keyphrases
- neuropathic pain
- double blind
- placebo controlled
- clinical trial
- spinal cord
- spinal cord injury
- phase iii
- chemotherapy induced
- phase ii
- major depressive disorder
- study protocol
- healthcare
- randomized controlled trial
- open label
- case control
- radiation therapy
- replacement therapy
- adverse drug
- electronic health record
- bipolar disorder
- irritable bowel syndrome